Collectively, these results demonstrate that DOT1L inhibition effectively attenuates the growth of ovarian cancer cells, suggesting that DOT1L pharmacological inhibition can be employed for the treatment of ovarian cancer. The gene discussed is DOT1L; the disease is ovarian cancer.